Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2017

Pharma News, 2017

Dr. Reddy's, fighting to recover from FDA warning letter, recalls 500K heartburn tablets
Dr. Reddy's, fighting to recover from FDA warning letter, recalls 500K heartburn tablets
Still struggling to turn its manufacturing around, Dr.
FDA warns Meridian of violations for lead-testing devices
FDA warns Meridian of violations for lead-testing devices
(Reuters) - The U.
US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes
US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes
LONDON, UK I October 23, 2017 I AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Bydureon BCise (exenatide extended-release) injectable suspensio...
Bayer makes 2 consumer health appointments
Bayer makes 2 consumer health appointments
WHIPPANY, N.
GSK wins U.S. shingles vaccine approval, UK nod for gene therapy
GSK wins U.S. shingles vaccine approval, UK nod for gene therapy
LONDON (Reuters) - GlaxoSmithKline has won U.
Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care
Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care
(Reuters) - Drugmaker Merck & Co Inc (MRK.
Celgene abandons Crohn's drug trials, shares drop
Celgene abandons Crohn's drug trials, shares drop
(Reuters) - Celgene Corp said it would abandon testing a drug to treat Crohn’s disease, in a major setback to the U.
Novartis blames site closure on pricing pressure in US generics market
Novartis blames site closure on pricing pressure in US generics market
Novartis’ (NOVN.
U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Patients with Resected High-Risk Advanced Melanoma and Grants Priority Review
U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Patients with Resected High-Risk Advanced Melanoma and Grants Priority Review
PRINCETON, N.
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy
FOSTER CITY, Calif.
U.S. District Court for the Eastern District of Texas Issues Adverse Trial Decision Concerning RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patents
U.S. District Court for the Eastern District of Texas Issues Adverse Trial Decision Concerning RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patents
DUBLIN, Oct.
Johnson & Johnson drops sirukumab after FDA blow, cans phase 3 AML trial
Johnson & Johnson drops sirukumab after FDA blow, cans phase 3 AML trial
Five months ago, Johnson & Johnson painted sirukumab and talacotuzumab as part of a wave of blockbusters-in-waiting that would drive growth for years to come.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand